Coronavirus Vaccine in Works From Jim Simons-Backed Codagenix |

Hedge fund billionaire Jim Simons is backing biotech firm Codagenix and its development of a potential coronavirus vaccine, Bloomberg reported Wednesday.
The founder of Renaissance Technologies holds at least a 25% stake in the drug developer and stands to win big from an effective vaccine.
Codagenix expects to have a vaccine ready for human trials in roughly 10 weeks, co-founder Robert Coleman told Bloomberg.
Visit the Business Insider homepage for more stories.

Thanks for signing up!

Access your favorite topics in a personalized feed while you're on the go. download the app

Biotech company Codagenix is developing a coronavirus vaccine, and hedge fund billionaire Jim Simons stands to win big if it proves effective.

The founder of Renaissance Technologies bought into the small drug developer four years ago and now owns at least 25% of the firm, Bloomberg reported Wednesday. Codagenix has a private market valuation between $50 million and $100 million as of January 18, according to PrivCo data cited by Crunchbase.

The company expects to have a vaccine for animal testing ready in four to six weeks and a vaccine for human trials prepared roughly six weeks later, Codagenix co-founder Robert Coleman told Bloomberg.

"It still takes a while to get a vaccination program underway," Simons told Bloomberg on Tuesday.

Codagenix began researching coronavirus drugs in January and had established frameworks for numerous potential vaccines in February, according to Bloomberg. The firm is now testing the vaccines to see which is best suited for trials.

Codagenix isn't the only biotech player rushing to offer solutions amid the escalating outbreak. Moderna announced on Monday it had submitted the first potential coronavirus vaccine for human testing in the US. The biotech's stock jumped 60% from Monday to Wednesday despite the broader stock market plummeting on virus fears.

Shares of biotech firm Gilead similarly spiked on Monday after a World Health Organization official said its experimental coronavirus drug may be the best shot at treating the virus-related COVID-19 disease. The stock jumped as much as 6.9% on Monday to hit a 16-month high.

The coronavirus epidemic has killed more than 2,800 people and infected more than 82,000 as of Thursday morning. The virus has spread to at least 40 countries after originating in Wuhan, China. Though the infection rate has slowed in China, new deaths outside the country raised new concerns of the outbreak escalating to a pandemic.

Simons, 81, is worth about $21.8 billion, according to the Bloomberg Billionaires Index.

Now read more markets coverage from Markets Insider and Business Insider:

Goldman Sachs says the S&P 500 could quickly fall another 7% on coronavirus fears — and warns US firms won't generate any profit growth in 2020

Bond king Jeff Gundlach claims Bernie Sanders is responsible for the market sell-off — even as other experts cite coronavirus fear

Bridgewater co-CEO Eileen Murray — one of the most powerful women in finance — explains why sponsorships, not mentorships, are the best way to help people succeed

ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKpom5%2BnvK%2Bt1aKprqtdq66kr8innGaclauyrbvPppynrF2ftq550qKkqKajYrCwsMCgnKehqGKvqrvTnpqhZZiasaixjJ%2Bsp5xdl7atuMiopZqhopp6c3yRaWRrZWFlf3mFk29tbWw%3D

Coronavirus Vaccine in Works From Jim Simons-Backed Codagenix

CATALOG

FEATURED TAGS